Disclosure of payments made to HCPs in Ireland

In recent years GSK has challenged the traditional commercial model of pharmaceutical companies with industry-leading improvements to how we do business. Our improvements aim to meet society’s growing expectation for organisations and individuals to act with transparency. This includes relationships between our industry and healthcare professionals (HCPs) or healthcare organisations (HCOs) so all of these interactions are conducted with integrity and transparency.

As members of the Irish Pharmaceutical Healthcare Association (IPHA), we fully support the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations.  This is now the second year of disclosure of these transfer of values.

GSK disclosures for Ireland for 2016 may be viewed here 

Key points for 2016 include

  • Our 2016 data confirms that we continue to lead the industry in its journey towards greater transparency and we fully support the IPHA disclosure initiative as a step in the right direction for the industry and society.
    • That is why we continue to implement the code in the true spirit in which it is intended; which means we will strive to named individual disclosure where required under the EFPIA Disclosure Code as the rule and disclose on an aggregate basis only for payments relating to Research and Development (as stipulated under the EFPIA Disclosure Code) or otherwise by exception
    • For 2016, we had a 100% individual consent rate for our disclosures: GSK has a ‘no consent, no contract’ policy – which means that GSK will not engage HCPs or HCOs that are not willing to agree to named disclosure of ToV. Given how important the relationship between Pharma companies and HCPs is, we want to do everything we can to ensure these relationships are fully transparent so there is no room for any misperceptions of conflicts of interest.

More information on our approach to the EFPIA code, how we are leading improvements to industry practices, and the importance of our partnerships with HCPs and HCOs can be found below, and is set out in greater detail here.

Leading the industry

Our changes at GSK go further than the current industry codes and therefore others in the industry:  As of 1 January 2016, as part of a number of key changes to how we work with HCPs, GSK ended payments to external HCPs to speak about our prescription medicines or vaccines to audiences who can prescribe or influence prescribing. Since then, GSK also stopped providing financial support directly to individual HCPs to attend medical congresses, and instead now provides funding to independent bodies which select HCPs to attend such congresses.

We continue to work with HCPs for non-promotional activities such as clinical research. Our disclosure figures for example include sponsorship for travel and registration fees to attend medical congresses and grants to HCOs. Transfers of value to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.

We believe these disclosures will help create a better understanding of how the pharmaceutical industry works with HCPs and HCOs. Given the measures GSK has put in place we seek to increase confidence in, and understanding of, how and why we work with healthcare professions for the sustainable improvement of healthcare and in the best interests of patients.